The funding comes under the AHG Catalysing Innovation Awards, part of the Addiction Healthcare Goals programme led by the Office for Life Sciences
If approved, DTX401 would be the first treatment to address the disease at its root cause
BLA is based on a robust data package supporting similarity to Orencia (abatacept) IV for infusion through totality of evidence including pharmacokinetic (PK) data
The new lineup features everything from the Color Fixation and Hair Therapy ranges to the Balanced Cleansing Shampoo and Nourishment & Protection Conditioner
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major
Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization
If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations
The agreement will see the two companies jointly develop and commercialise premium nutraceutical ingredients in advanced transdermal delivery formats
The results mark a potential breakthrough for patients living with CIndU, a condition with limited treatment options
Subscribe To Our Newsletter & Stay Updated
